AI-Native Scoping Reviews & Evidence Mapping

This review maps 260 original studies and 80,624 participants into a practical evidence layer on where coil embolization helps in aortic aneurysm repair — especially type II endoleak prevention, sac behavior, and staged spinal-cord-protection strategies. It also shows the trade-offs that matter clinically: recurrent endoleaks, buttock claudication, radiation exposure, infection risk, coil migration, and when coils, plugs, Onyx, NBCA, or anatomy-driven alternatives may be preferable.

This paper shows that coffee is not a proven anti-aging therapy, yet the mapped evidence still suggests a biologically plausible link to longer survival through oxidative-stress and insulin/IGF-1 pathways, with human data pointing to modest benefit rather than clear harm. Read the full text to see where the real signal lies, which findings are only indirect or genotype-specific, and why the apparent longevity story of coffee is much more nuanced than popular health claims suggest.

CLTI prognosis is not decided by the artery alone: this evidence map shows that wound severity, nutrition, frailty, heart failure, dialysis, mobility loss, and biomarkers together define who survives, heals, or loses a limb. The full review explains which clinical scores and warning signals may help identify high-risk patients before revascularization decisions are made.

This paper shows that vascular calcification in CKD is not a passive byproduct of renal failure, but an active, biologically driven process fueled by phosphate burden, uremic toxins, inflammation, and VSMC transdifferentiation. The full paper is worth reading because it maps where the strongest mechanistic and clinical signals converge across 1,230 original studies, and highlights which biomarkers and interventions may actually become actionable in routine CKD care.

Y chromosome loss emerges in this paper not as a passive marker of ageing, but as a potentially central male-specific biological signal linked to cardiovascular death, cancer progression, neurodegeneration, and immune dysfunction across a massive evidence base. The full paper is worth reading because it shows where this signal is strongest, how consistent it is across 1,048 original studies, and why LOY may become both a prognostic biomarker and a future therapeutic target.

This paper shows that the choice between carotid endarterectomy and carotid stenting is not just a technical preference, but a clinically meaningful trade-off between stroke risk, myocardial infarction risk, and long-term durability. Read the full paper to see which patients truly benefit from CEA as the default option, where CAS still has a justified role, and how 670 original studies map the evidence behind that decision.

PSV is not just a number for grading carotid stenosis—it can signal restenosis risk, hemodynamic compromise, plaque instability, and response to revascularization, but only when interpreted in the right anatomical and technical context. Read the full paper to see where PSV truly adds clinical value, where it can mislead, and how the evidence supports smarter carotid ultrasound decision-making.

This paper shows that carotid stenosis is not a rare incidental finding but a patterned disease concentrated in stroke, TIA, and clearly defined high-risk groups—while broad screening in low-yield populations adds little. It is worth reading because it maps where carotid imaging truly matters and why future risk assessment may need to move beyond percent narrowing toward plaque vulnerability.

Carotid stenosis outcomes are not determined by narrowing alone: this review shows how symptom status, procedure choice, restenosis, and plaque vulnerability markers can decisively shift stroke risk and long-term prognosis. Read the full paper to see which patients appear to benefit from intervention, where CEA and CAS truly diverge, and why modern risk stratification may need to move beyond luminal stenosis.

This paper shows that in carotid stenosis, the real difference is not only who gets operated on, but who receives and continues the right medical therapy. It is worth reading because it identifies the medication strategies that most consistently align with better outcomes and exposes adherence as a major, underappreciated driver of prognosis.

This paper shows that carotid stenosis is not just a problem of how narrow the artery looks: inflammation repeatedly emerges as the hidden biology that helps explain which plaques become dangerous, embolize, and lead to recurrent stroke. The full review is worth reading because it maps where PET imaging, blood biomarkers, and anti-inflammatory strategies may move carotid care beyond stenosis grading alone toward a more precise, risk-based treatment model.